Follow us for updates
© 2022
Read the Story →

How to Take Lagundi for Mild COVID Symptoms, from DOST

Follow the prescribed dosage.
by Arianne Merez
Jan 20, 2022
Photo/s: Shutterstock

Taking Lagundi can relieve symptoms of mild COVID-19, the Department of Science and Technology said Thursday as it emphasized the need to follow the right dosage.

Clinical trials by researchers from the University of the Philippines-Manila showed that Lagundi can alleviate symptoms of mild COVID-19 such as cough and loss of smell, DOST Usec. Rowena Guevarra said.

"Base sa research, walang ibang epekto sa katawan ang Lagundi kapag sinunod ang prescribed dosage," Guevarra said in televised briefing.

Adults with mild COVID-19 are suggested to take 600 milligrams of Lagundi--either in capsule or syrup form--three times a day for 10 days according to Guevarra. Lagundi capsules or syrup can be bought at pharmacies.

Last year, the DOST also recommended taking virgin coconut oil since clinical trials show that it can help reduce the symptoms of COVID-19 faster.

READ: Virgin Coconut Oil Can Supplement COVID Treatment: DOST

The Philippines has been grappling with a renewed surge in COVID-19 infections since the start of the year driven by the more contagious omicron variant.

Continue reading below ↓

The surge has prompted households to stock up on common flu medicines prompting the government to put a purchase limit on the said drugs.

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
He wins the World's Ugliest Dog Contest.
With the reopening of several local destinations, this app has never been more timely.
Third crown for the country in the pageant for trans women.
Some relief from rising prices.
Landmark Roe vs Wade ruling of 1973 is overturned.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.